These results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in previous studies.
Prof. Guido Kroemer’s team, from Gustave Roussy, will test Tollys’ specific TLR3 agonist, TL-532, to restore deficient chemotherapeutic responses in the context of FPR1 deficiency. FPR1 deficiency affects 30% of world population and is associated with precocious manifestation of breast, colorectal, esophageal, head and neck carcinomas.
Based on the strong preclinical data collected to date with locally administered TL-532, Tollys is accelerating and expanding its internal and collaborative R&D activities on TLR3 agonist candidates designed for intravenous administration and antibody-drug-conjugates.
Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. As an expert in clinical oncology and drug development, Nasser Azli is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532.
The new 300 sqm headquarters will support Tollys’ growth by offering all the features expected by biotech companies. This move to our new headquarters allows our team to work not only in our own research laboratories but also near the scientific and medical communities. This new space is specifically designed for biotech companies and will support our developments very efficiently.
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the EACR 2021 Congress, which will take place from June 9 -12. We’re proud to be able to share this data, which proves the potential of this specific TLR3 agonist in immuno-oncology, in particular by releasing tumor-specific antigens.